气泡分化驱动阻力KRAS抑制在肺腺癌的抵抗
Zhuxuan Li1,2, Xueqian Zhuang1, Chun-Hao Pan1
1Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer discovery
|November 6, 2023
概括
克拉斯抑制剂在肺腺癌 (LUAD) 中面临抵抗. 向AT1样细胞,一种耐药状态,提高了KRAS抑制剂的疗效,为LUAD治疗提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 肺腺癌 (LUAD) 是癌症死亡的主要原因,通常是由KRAS突变驱动的.
- 由于耐药性,现有的KRAS抑制剂的临床益处有限.
- LUAD起源于膜2型 (AT2) 细胞,它们充当干细胞.
研究的目的:
- 研究LUAD中对KRAS抑制剂的耐药性机制.
- 确定潜在的治疗策略,以克服治疗耐药性.
主要方法:
- 利用了基因工程小鼠模型,患者衍生的异种移植和患者样本.
- 研究了KRAS抑制对LUAD细胞状态和分化的影响.
- 评估了向AT1样细胞对治疗反应的影响.
主要成果:
- 在LUAD中,KRAS抑制促进了静止的AT1样癌细胞状态.
- 在正常的AT2细胞中抑制KRAS诱导AT1分化.
- 类似AT1的LUAD细胞可以在停止治疗后重新点燃瘤生长.
- 切除AT1-样细胞显著改善了对KRAS抑制剂的反应.
结论:
- 在LUAD中,KRAS在推动内异质性方面发挥着作用.
- 向膜分化是一个有前途的策略,可以增强针对KRAS的治疗方法.
- 通过向AT1-样细胞来克服耐药性,为LUAD提供了一个新的治疗途径.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
